Could a common diabetes drug lift depression in HIV patients?
NCT ID NCT07007221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether metformin, a standard diabetes drug, can help treat depression in people living with HIV. Researchers will enroll 600 adults with HIV and depression, giving them metformin, fluoxetine (a standard antidepressant), both, or a placebo for up to 12 weeks. The goal is to see if metformin improves mood and reduces inflammation, potentially offering a new, accessible treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin
What this could lead to
If it works, this could offer a new, affordable way to treat depression in people with HIV, improving both mental health and HIV outcomes.
What could go wrong
This is an early phase 2 trial with multiple parts, so results are uncertain. Depression is complex, and metformin may not work for everyone or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••